TR201722630A2 - - Google Patents

Download PDF

Info

Publication number
TR201722630A2
TR201722630A2 TR2017/22630A TR201722630A TR201722630A2 TR 201722630 A2 TR201722630 A2 TR 201722630A2 TR 2017/22630 A TR2017/22630 A TR 2017/22630A TR 201722630 A TR201722630 A TR 201722630A TR 201722630 A2 TR201722630 A2 TR 201722630A2
Authority
TR
Turkey
Prior art keywords
pharmaceutically acceptable
dabigatran etexilate
oral administration
free base
relates
Prior art date
Application number
TR2017/22630A
Other languages
English (en)
Inventor
Palantöken Arzu
Türkyilmaz Ali̇
Gülkok Yildiz
Yavuz Büşra
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/22630A priority Critical patent/TR201722630A2/tr
Priority to PCT/TR2018/050919 priority patent/WO2019151966A2/en
Priority to EP18899013.9A priority patent/EP3731824B1/en
Publication of TR201722630A2 publication Critical patent/TR201722630A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, dabigatran eteksilat serbest bazını veya dabigatran eteksilatın farmasötik olarak kabul edilebilir tuzlarını ve en az bir farmasötik olarak kabul edilebilir eksipiyan içeren, oral uygulamaya yönelik farmasötik tablet kompozisyonları ile ilgilidir.
TR2017/22630A 2017-12-28 2017-12-28 TR201722630A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/22630A TR201722630A2 (tr) 2017-12-28 2017-12-28
PCT/TR2018/050919 WO2019151966A2 (en) 2017-12-28 2018-12-27 Pharmaceutical tablet compositions of dabigatran
EP18899013.9A EP3731824B1 (en) 2017-12-28 2018-12-27 Pharmaceutical tablet compositions of dabigatran

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/22630A TR201722630A2 (tr) 2017-12-28 2017-12-28

Publications (1)

Publication Number Publication Date
TR201722630A2 true TR201722630A2 (tr) 2019-07-22

Family

ID=67180856

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/22630A TR201722630A2 (tr) 2017-12-28 2017-12-28

Country Status (3)

Country Link
EP (1) EP3731824B1 (tr)
TR (1) TR201722630A2 (tr)
WO (1) WO2019151966A2 (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
SI1870100T1 (sl) * 2002-03-07 2012-05-31 Boehringer Ingelheim Int Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
SI2588090T1 (sl) 2010-07-01 2017-06-30 Krka, D.D., Novo Mesto Trdne peroralne farmacevtske oblike, ki obsegajo dabigatran eteksilat in njegove farmacevtsko sprejemljive soli
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
ES2895918T3 (es) 2012-02-21 2022-02-23 Towa Pharmaceutical Europe S L Composiciones farmacéuticas orales de dabigatrán etexilato
WO2015145462A1 (en) * 2014-03-26 2015-10-01 Cadila Healthcare Limited Pharmaceutical compositions of dabigatran
CN105919962B (zh) * 2015-12-18 2019-01-18 重庆两江药物研发中心有限公司 一种达比加群酯片剂及其制备方法
EP3332771A1 (en) * 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayered tablet compositions of dabigatran

Also Published As

Publication number Publication date
WO2019151966A2 (en) 2019-08-08
EP3731824A2 (en) 2020-11-04
EP3731824B1 (en) 2023-03-15
WO2019151966A3 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
CY1124007T1 (el) Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
CY1122024T1 (el) Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch
MA41265B1 (fr) Compositions pour administration de médicaments iléo-jéjunal.
EA201792591A1 (ru) Фармацевтические препараты
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
JOP20210090A1 (ar) مشتقات بيريدينيل سلفوناميد، تركيبات صيدلانية واستخداماتها
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
IN2014MN02245A (tr)
TR201906685T4 (tr) Kristalin macitentan içeren farmasötik bileşim.
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
MX2023012198A (es) Composiciones de amantadina, preparaciones de estas y metodos de uso.
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
CY1123185T1 (el) Παραγωγα ινδολιου
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
EA201892529A1 (ru) Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы
MX385513B (es) Composiciones farmaceuticas que comprenden safinamida.
TR201914406A2 (tr) Sapropteri̇n di̇hi̇droklorür ve en az bi̇r farmasöti̇k eksi̇pi̇yan i̇çeren kati oral farmasöti̇k formülasyonlar
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
WO2019004980A3 (en) SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE